Denali Therapeutics Inc Earnings

Denali Therapeutics Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2025. On a quarterly growth basis, Denali Therapeutics Inc has generated NaN% jump in its revenue since last 3-months.

Denali Therapeutics Inc’s net profit fell -30.62% since last year same period to $-132.97Mn in the Q1 2025. On a quarterly growth basis, Denali Therapeutics Inc has generated -15.87% fall in its net profits since last 3-months.

Denali Therapeutics Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2025. On a quarterly growth basis, Denali Therapeutics Inc has generated NaN% jump in its net profit margins since last 3-months.

Denali Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.7 - a 16.74% jump from last quarter’s estimates.

Denali Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.7.

Denali Therapeutics Inc’s earning per share (EPS) jumped 0% since last year same period to -0.78 in the Q1 2025. This indicates that the Denali Therapeutics Inc has generated 0% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Denali Therapeutics Inc’s return on assets (ROA) stands at -0.23.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Denali Therapeutics Inc’s return on equity (ROE) stands at -0.35.